Filing Details

Accession Number:
0001104659-21-110763
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-08-30 09:08:55
Reporting Period:
2021-08-27
Accepted Time:
2021-08-30 09:08:55
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1561743 Kindred Biosciences Inc. KIN Pharmaceutical Preparations (2834) 461160142
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1739104 Elanco Animal Health Inc 2500 Innovation Way
Greenfield IN 46140
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, Par Value $0.0001 Acquisiton 2021-08-27 45,508,938 $9.25 10,000 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
Footnotes
  1. Pursuant to the Agreement and Plan of Merger, dated as of June 15, 2021 and as amended on June 30, 2021, by and among Elanco Animal Health Incorporated, Knight Merger Sub, Inc., a wholly owned subsidiary of Elanco Animal Health Incorporated ("Merger Sub"), and Kindred Biosciences, Inc. ("KindredBio"), Merger Sub merged with and into KindredBio (the "Merger") on August 27, 2021. Upon completion of the Merger, each share of common stock of KindredBio that was issued and outstanding immediately prior to the effective time of the Merger was cancelled, and each share of common stock of Merger Sub was converted into one share of common stock of the surviving corporation. Consequently, upon the consummation of the Merger on August 27, 2021, Elanco became the owner of 10,000 shares of common stock of the surviving corporation, representing 100% of the issued and outstanding shares of common stock of the surviving corporation.